Haschek H, Schmidbauer C P
Aktuelle Gerontol. 1979 Dec;9(12):549-57.
A brief discussion of the aetiology and epidemiology of renal carcinomas is followed by a description of the clinical features. Attention is drawn to the significance of symptoms emphasizing the importance of early diagnosis. Intravenous urography still remains as the most important diagnostic procedure. It is pointed out that sonography and computer-tomography are now established as newer diagnostic methods, i.e. in distinguishing between cyst and tumor, in renal masses. Therapy, is still based upon surgical treatment. Transperitoneal, radical tumornephrectomy as compared with simple lumbar nephrectomy, has improved 5-year survival rate up to 16% especially in stage III tumors. Extracorporeal surgery for single kidney patients as hyperthermic surgery constitute new surgical methods, but only for specifically equiped urologic clinics. Embolisation of renal cell carcinoma is also used as therapeutic management in largely progressed tumors, and also used, as a preoperative measure, for the reducement of tumor size. Irradiation, before and after surgical treatment, as well as cytostatic therapy, revealed no significant improvement. We have reason to hope that progress in the research of hormonal- and immunotherapy will improve 5-year survival rate, in renal cell carcinoma.
在简要讨论肾癌的病因学和流行病学之后,描述了其临床特征。强调了症状的重要性,突出了早期诊断的意义。静脉尿路造影仍然是最重要的诊断方法。指出超声检查和计算机断层扫描现已成为新的诊断方法,即在鉴别肾肿块中的囊肿和肿瘤方面。治疗仍以手术治疗为基础。与单纯的腰部肾切除术相比,经腹根治性肿瘤肾切除术使5年生存率提高了16%,特别是在III期肿瘤患者中。对于单肾患者的体外手术,如高温手术,构成了新的手术方法,但仅适用于配备特殊设备的泌尿外科诊所。肾细胞癌的栓塞术也被用作晚期肿瘤的治疗手段,并且也作为术前措施用于缩小肿瘤大小。手术前后的放疗以及细胞抑制疗法均未显示出显著改善。我们有理由希望激素疗法和免疫疗法的研究进展将提高肾细胞癌的5年生存率。